Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$IONS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.69 down -188.46% YoY • Reported revenue of $268M down -40.71% YoY • Ionis Pharmaceuticals remains on track to achieve its 2026 financial guidance, including full-year product sales targets for TRYNGOLZA and DAWNZERA, while maintaining its goal of cashflow breakeven in 2028.

Price since post

Full Details

Advertisement|Remove ads.